US 12,440,169 B2
Determining prospective risk of heart failure hospitalization
Vinod Sharma, Maple Grove, MN (US); Eduardo N. Warman, Maple Grove, MN (US); and Karen J. Kleckner, Blaine, MN (US)
Assigned to Medtronic, Inc., Minneapolis, MN (US)
Filed by Medtronic, Inc., Minneapolis, MN (US)
Filed on Dec. 13, 2018, as Appl. No. 16/218,694.
Application 16/218,694 is a division of application No. 14/798,225, filed on Jul. 13, 2015, granted, now 10,172,568.
Claims priority of provisional application 62/037,895, filed on Aug. 15, 2014.
Claims priority of provisional application 62/024,285, filed on Jul. 14, 2014.
Prior Publication US 2019/0110756 A1, Apr. 18, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 5/0205 (2006.01); A61B 5/0537 (2021.01); A61B 5/11 (2006.01); A61B 5/145 (2006.01); A61B 5/339 (2021.01); A61B 5/361 (2021.01); A61B 5/363 (2021.01); G16H 20/00 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01)
CPC A61B 5/7275 (2013.01) [A61B 5/0031 (2013.01); A61B 5/0205 (2013.01); A61B 5/14503 (2013.01); A61B 5/14532 (2013.01); A61B 5/14535 (2013.01); A61B 5/14546 (2013.01); A61B 5/339 (2021.01); A61B 5/4836 (2013.01); A61B 5/686 (2013.01); A61B 5/7278 (2013.01); A61B 5/7435 (2013.01); A61B 5/7475 (2013.01); G16H 20/00 (2018.01); G16H 20/40 (2018.01); G16H 50/20 (2018.01); G16H 50/30 (2018.01); A61B 5/0036 (2018.08); A61B 5/0537 (2013.01); A61B 5/1118 (2013.01); A61B 5/361 (2021.01); A61B 5/363 (2021.01); A61B 5/6869 (2013.01); A61B 2505/07 (2013.01)] 4 Claims
 
1. A method of operation of a medical system for determining prospective heart failure hospitalization (HFH) risk, the method comprising:
providing one or more implantable sensors to detect one or more patient metrics;
detecting, using the one or more implantable sensors, the one or more patient metrics;
determining, using a computing device in communication with the implantable sensors, a number of an individual heart failure patient's detected data observations during an individual evaluation period, the detected data observations comprising a number of times each of the one or more patient metrics detected by the one or more implantable sensors exceeds a representative value, the one or more detected patient metrics comprising one or more of an atrial tachycardia/atrial fibrillation (AT/AF) daily burden, a time in AT/AF, a night heart rate (NHR), an intrathoracic impedance, a thoracic impedance, heart rate variability, ventricular intrinsic pacing rate, atrial intrinsic pacing rate, heart rate, respiration rates, tidal volume, an atrial defibrillation duration, a ventricular contraction rate during atrial fibrillation, a cardiac resynchronization therapy percentage, a mean ventricular rate during AT/AF, and a V rate;
employing, using the computing device, a lookup table to determine prospective heart failure hospitalization risk based upon the determined number of the detected data observations during the said individual evaluation period;
displaying, on a graphical user interface in communication with the computing device, the prospective risk of HFH;
using the prospective risk to suggest a therapy;
displaying on the graphical user interface the therapy or transmitting the therapy;
using the prospective risk to modify therapy delivered by an implantable medical device; and
delivering the modified therapy to the patient using the implantable medical device;
wherein the lookup table comprises a set of data observations categories and for each said category a stored ratio;
wherein each said data observations category defines a total number of group data evaluation periods each having a defined same number of data observations from a population of patients therein; and
wherein the stored ratio for each said data observations category comprises a ratio of heart failure hospitalizations associated with the said data observations category to the total number of group evaluation periods within the said data observations category.